Jialiken Dinala, Qian Lichao, Wen Shiwu, Ren Shuai, Fan Yadong, Dong Yi Xuan, Zou Chong
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Eur J Med Res. 2025 Jan 3;30(1):1. doi: 10.1186/s40001-024-02193-9.
Astragalus injection has been utilized in traditional Chinese medicine to treat a variety of diseases. The purpose of this systematic review was to evaluate the effectiveness of Astragalus injection in the treatment of viral myocarditis.
English databases such as PubMed, Cochrane Library, and EMBASE, and Chinese databases of Sino Med, China National Knowledge Infrastructure (CNKI), the VIP Information Resource Integration Service Platform, and Wanfang Data Information Site, were searched from their inception until May 1, 2024. The outcome measures of this study included the effectiveness rate, creatine kinase (CK), aspartate aminotransferase (AST), creatine kinase Isoenzyme (CK-MB), lactate dehydrogenase (LDH), cardiac troponin I (cTnI), and electrocardiogram (ECG).
Twenty-six studies were included in this analysis, comprising a total of 2793 patients. Meta-analyses indicated that, compared to standard treatment alone, the Astragalus injection group demonstrated significant advantages, achieving an effectiveness rate of 92.79% (1094 cases). In contrast, the control group, which included 1108 cases, had an effectiveness rate of 77.71% (861 cases). Additionally, the Astragalus injection group exhibited the following benefits for patients affected by viral myocarditis: decreasing ∆AST [weighted mean difference (WMD) = - 14.23, 95% confidence interval (CI) (- 24.17, - 4.30), P < 0.05]; ∆CK [weighted mean difference (WMD) = - 34.84, 95% confidence interval (CI) (- 48.03, - 21.65), P < 0.05], lowering ∆CK-MB [WMD = - 7.64, 95% CI (- 9.30, - 5.99), P < 0.001], ∆cTnl [WMD = - 0.18, 95% CI (- 0.27, - 0.10), P < 0.001], ∆LDH [WMD = -41.93, 95% CI (- 55.97, - 27.90), P < 0.05], and ∆cTnI [WMD = - 0.18, 95% CI (- 0.28, - 0.08), P < 0.05].
Astragalus injection may have a therapeutic effect in patients with viral myocarditis by reducing levels of AST, CK, CK-MB, LDH, and cTnI, improving ECG results, and increasing the overall effectiveness rate for those affected by this condition.
This study registered with PROSPERO before conducting the systematic review. The registration number is CRD42021239660.
黄芪注射液已被用于中医治疗多种疾病。本系统评价的目的是评估黄芪注射液治疗病毒性心肌炎的有效性。
检索英文数据库如PubMed、Cochrane图书馆和EMBASE，以及中文数据库中国生物医学文献数据库、中国知网、维普资讯资源整合服务平台和万方数据信息服务平台，检索时间从建库至2024年5月1日。本研究的结局指标包括有效率、肌酸激酶（CK）、天门冬氨酸氨基转移酶（AST）、肌酸激酶同工酶（CK-MB）、乳酸脱氢酶（LDH）、心肌肌钙蛋白I（cTnI）和心电图（ECG）。
本分析纳入26项研究，共2793例患者。荟萃分析表明，与单纯标准治疗相比，黄芪注射液组具有显著优势，有效率为92.79%（1094例）。相比之下，对照组有1108例，有效率为77.71%（861例）。此外，黄芪注射液组对病毒性心肌炎患者有以下益处：降低∆AST[加权均数差（WMD）=-14.23，95%置信区间（CI）（-24.17，-4.30），P<0.05]；∆CK[加权均数差（WMD）=-34.84，95%置信区间（CI）（-48.03，-21.65），P<0.05]，降低∆CK-MB[WMD=-7.64，95%CI（-9.30，-5.99），P<0.001]，∆cTnl[WMD=-0.18，95%CI（-0.27，-0.10），P<0.001]，∆LDH[WMD=-41.93，95%CI（-55.97，-27.90），P<0.05]，以及∆cTnI[WMD=-0.18，95%CI（-0.28，-0.08），P<0.05]。
黄芪注射液可能通过降低AST、CK、CK-MB、LDH和cTnI水平、改善心电图结果以及提高病毒性心肌炎患者的总体有效率，对病毒性心肌炎患者具有治疗作用。
本研究在进行系统评价之前在PROSPERO注册。注册号为CRD42021239660。
